Comparison ASP of Remicade vs biosimilars in the U.S. Q4 2024

Published by
Matej Mikulic,
Nov 28, 2024

As of Q4 2024, the average sales price (ASP) of autoimmune disease drug Remicade was 304 U.S. dollars, compared to 248 U.S. dollars for biosimilar Renflexis. This statistic illustrates a comparison of the ASP of Remicade vs biosimilars in the United States.

Comparison of the average sales price (ASP) of Remicade vs biosimilars in the United States as of Q4 2024 (in U.S. dollars)

Loading statistic...

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

October 2024

Region

United States

Survey time period

Q4 2024

Supplementary notes

* Janssen’s Remicade without the brand name.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Pharmaceutical industry in Norway "

The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Pharmaceutical industry in Norway

Overview

5

Pharmaceutical revenue

5

Production and trade

4

R&D, patents and new products

4

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Pharmaceutical industry in the UKGlobal pharmaceutical industryPharmaceutical industry in the U.S.AstraZenecaNational Health Service (NHS) UK
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.